Pharma Foods International Co., Ltd. AI Stock Analysis
Want to see JP:2929 full AI Analyst Report?
Pharma Foods International Co., Ltd. (2929) AI Stock Analysis
Pharma Foods International Co., Ltd.
(TSE/TYO:2929)
The score is held back primarily by weak recent cash generation (negative operating cash flow in 2025–2026 and deeply negative 2026 free cash flow) and still-elevated leverage. These risks are partly offset by supportive valuation (low P/E and ~3.17% dividend yield) and a strong technical uptrend, though momentum indicators are overbought and may limit near-term upside.
Pharma Foods International Co., Ltd. (2929) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 16.38B
- Dividend Yield
- 3.89%
- Average Volume (3M)
- 232.76K
- Price to Earnings (P/E)
- 8.3
- Beta (1Y)
- 0.83
- Revenue Growth
- -3.12%
- EPS Growth
- 406.78%
- Country
- Japan
- Employees
- 625
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Pharma Foods International Co., Ltd. Business Overview & Revenue Model
Company Description
Pharma Foods International Co., Ltd. is a Japanese enterprise dedicated to the research, development, and commercialization of ingredients for functional foods. Its diverse product portfolio features items such as Pharma-GABA, Bonepep, Ovopron (a spe...
How the Company Makes Money
Pharma Foods International primarily makes money by selling branded health-related consumer products, especially dietary supplements and other functional food/wellness items. Revenue is generated when customers purchase these products through the com...
Pharma Foods International Co., Ltd. Financial Statement Overview
Summary
Income statement trends are improving but uneven (revenue down in 2026, operating margin modest, and earnings volatility across years). Balance sheet leverage remains elevated (debt-to-equity ~1.30x). The biggest constraint is cash flow: operating cash flow was negative in both 2025 and 2026 and free cash flow was deeply negative in 2026, indicating weak cash conversion despite positive net income.
Income Statement
63PositiveBalance Sheet
55NeutralCash Flow
28Negative| Breakdown | TTM | Jul 2026 | Jul 2025 | Jul 2024 | Jul 2023 | Jul 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 63.22B | 63.22B | 65.26B | 62.15B | 68.57B | 60.19B |
| Gross Profit | 50.66B | 50.66B | 52.53B | 48.65B | 55.21B | 48.06B |
| EBITDA | 3.37B | 3.37B | 3.15B | 6.02B | 4.16B | 1.60B |
| Net Income | 1.99B | 1.99B | 368.00M | 3.21B | 3.08B | -374.00M |
Balance Sheet | ||||||
| Total Assets | 35.12B | 35.12B | 32.78B | 36.57B | 36.23B | 31.16B |
| Cash, Cash Equivalents and Short-Term Investments | 7.79B | 7.79B | 9.16B | 15.67B | 16.31B | 8.85B |
| Total Debt | 17.17B | 17.17B | 12.66B | 16.90B | 20.12B | 16.89B |
| Total Liabilities | 21.95B | 21.95B | 21.23B | 24.99B | 26.60B | 24.08B |
| Stockholders Equity | 13.17B | 13.17B | 11.55B | 11.59B | 9.63B | 7.07B |
Cash Flow | ||||||
| Free Cash Flow | -5.19B | -5.19B | -1.98B | 4.54B | 5.74B | -6.53B |
| Operating Cash Flow | -1.18B | -1.18B | -1.09B | 5.49B | 6.13B | -6.07B |
| Investing Cash Flow | -4.00B | -4.00B | -950.00M | -1.39B | -1.01B | -2.54B |
| Financing Cash Flow | 3.81B | 3.81B | -4.47B | -4.84B | 2.34B | 7.68B |
Pharma Foods International Co., Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:2929, the sentiment is Negative. The current price of 565.00 is below the 20-day moving average (MA) of 632.50, below the 50-day MA of 655.26, and below the 200-day MA of 624.86, indicating a bearish trend. The MACD of -29.53 indicates Positive momentum. The RSI at 25.73 is Positive, neither overbought nor oversold. The STOCH value of 18.82 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:2929.
Pharma Foods International Co., Ltd. Peers Comparison
Overall Rating
JP:452481.5Outperform
JP:454070Outperform- JP:292960Neutral
JP:453946.5Neutral
JP:451245Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| JP:4524 | 82Outperform | JPY 9.03B | 11.54 | ― | 2.93% | -0.47% | 50.82% |
| JP:4540 | 70Outperform | JPY 293.64B | 9.16 | 9.84% | 4.04% | 13.32% | 17.39% |
| JP:2929 | 60Neutral | JPY 16.40B | 8.27 | ― | 3.89% | -3.12% | 406.78% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| JP:4539 | 47Neutral | JPY 5.31B | -11.60 | ― | 3.27% | 0.31% | -194.72% |
| JP:4512 | 45Neutral | JPY 9.93B | 55.49 | ― | 1.22% | 23.41% | 149.71% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:2929 | Pharma Foods International Co., Ltd. | 565.00 | -203.59 | -26.49% | |
| JP:4540 | Tsumura & Co | 3914.00 | 253.36 | 6.92% | |
| JP:4512 | Wakamoto Pharmaceutical Co., Ltd. | 288.00 | 8.36 | 2.99% | |
| JP:4524 | Morishita Jintan Co., Ltd. | 2222.00 | 144.59 | 6.96% | |
| JP:4539 | Nippon Chemiphar Co., Ltd. | 1528.00 | 47.18 | 3.19% |
Pharma Foods International Co., Ltd. Corporate Events
Pharma Foods International Completes Acquisition of Medical Food Firm Marine Pro Foods
Pharma Foods International has completed its acquisition of all shares in Marine Pro Foods, turning the Tokyo-based medical food developer into a wholly owned subsidiary. The deal brings Marine Pro Foods’ portfolio of agricultural, livestock, marine,...
Pharma Foods Secures Overdraft Facility to Fund Marine Pro Foods Acquisition
Pharma Foods International Co., Ltd., a player in the functional foods and nutraceuticals market, develops and sells health-oriented food products aimed at consumers seeking added nutritional and wellness benefits. The company is listed on the Tokyo...
Pharma Foods Launches 1K Project Plan to Drive Profit Growth and Medical Food Expansion
Pharma Foods International has approved a new medium-term management plan, the 1K Project – SPRING Strategy, covering fiscal years 2027 to 2029 and centered on strengthening profitability and enhancing corporate value. The plan shifts emphasis from s...
Pharma Foods to Acquire Marine Pro Foods in ¥5.03 Billion Medical Foods Push
Pharma Foods International has approved the acquisition of all shares of Marine Pro Foods, a medical foods specialist, making it a wholly owned subsidiary under its M&A-focused “New Value Creation 1K Project” growth strategy. Marine Pro Foods supplie...
Pharma Foods International Releases FY2026 Consolidated Results
Pharma Foods International Co., Ltd. has released its consolidated financial results for the fiscal year ended July 31, 2026, along with supplementary materials summarizing full-year performance. While specific figures are not disclosed in the releas...
Pharma Foods International Corrects Net Asset Data in FY2026 Results
Pharma Foods International has announced corrections to numerical data in its consolidated financial results for the fiscal year ended July 31, 2026, prepared under Japanese GAAP. The revisions relate to items in the consolidated balance sheet, speci...
Pharma Foods Profit Soars Despite Lower Sales, Eyes Further Gains in 2027
Pharma Foods International reported a 3.1% decline in net sales to ¥63.2 billion for the year ended July 31, 2026, but operating profit rose 11.2% to ¥2.6 billion and profit attributable to owners of parent surged to ¥2.0 billion, lifting ROE to 16.1...
Pharma Foods Books Impairment Loss on Onkyo Investment with Limited Consolidated Impact
Pharma Foods International Co., Ltd. has booked a special loss in its non-consolidated results for the fiscal year ended July 2026, after recognizing an impairment on its equity-method investment in Onkyo Corporation. The company concluded that recov...
Pharma Foods Raises Profit Outlook Despite Lower Sales in FY2026
Pharma Foods International has revised its full-year forecasts for the fiscal year ended July 2026, projecting lower net sales but higher profits than previously expected. Net sales are now seen at JPY 63.2 billion versus a prior JPY 67 billion, whil...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 12, 2026